Pfizer provides $2 million grant for cancer research

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Pfizer, Inc. provided a $2 million grant to the National Comprehensive Cancer Network (NCCN) to be used to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors and being studied in a range of solid tumors.

"This grant from Pfizer supports basic and clinical research designed and carried out by investigators at NCCN member institutions with the overall goal of improving patient survival and quality of life," NCCN chief executive officer William T. McGivney said in a news release.

The NCCN is a not-for-profit alliance of 20 leading cancer centers.

Pfizer is a New York-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.